Literature DB >> 9214452

Co-expression and regulation of Met and Ron proto-oncogenes in human hepatocellular carcinoma tissues and cell lines.

Q Chen1, D W Seol, B Carr, R Zarnegar.   

Abstract

Met and ron proto-oncogenes encode the cell surface receptors for hepatocyte growth factor (HGF) and hepatocyte growth factor-like (HLP) protein, respectively, and induce mitogenesis, motogenesis, morphogenesis, and metastatic activity in various cell types. Overexpression of met in human carcinoma has been reported by several groups including ours; however, the mechanisms that control met gene expression are thus far unclear. The present study focuses on the expression and regulation of the Met and Ron receptors in human hepatocellular carcinoma (HCC). We report here that abnormal expression of met and ron proteins occurs in some cases of human HCC. Using several HCC cell lines as a model system, we show that HGF, as well as other cytokines, such as epidermal growth factor (EGF), interleukin-1 (IL-1), interleukin-6 (IL-6), and tumor necrosis factor alpha (TNF-alpha), induce met and ron expression. Using several chimeric constructs consisting of various lengths of the met promoter region fused to the reporter gene of chloramphenicol acetyl transferase (CAT), and by performing transient transfection of these constructs into HepG2 cells, we show that induction of met gene expression by HGF and other cytokines is, at least in part, through up-regulation of met gene promoter activity. The DNA region conferring responsiveness to cytokine induction was located within 0.2 kb of the met core promoter. Interestingly, EGF did not stimulate met promoter activity in any of the met-CAT chimeric constructs. These results provide evidence that met and ron are modulated in the liver by a similar cytokine network. In the case of met expression, the 0.2-kb region in the met gene promoter may play an important role in mediating its gene induction in response to HGF and other cytokines. Our results also suggest that unregulated expression of met and ron may be associated with pathological conditions, such as HCC, in the liver.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9214452     DOI: 10.1002/hep.510260108

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  34 in total

1.  Two polymorphisms of USF1 gene (-202G>A and -844C>T) may be associated with hepatocellular carcinoma susceptibility based on a case-control study in Chinese Han population.

Authors:  Xu Zhou; Hua-qiang Zhu; Chao-qun Ma; Hong-guang Li; Fang-feng Liu; Hong Chang; Jun Lu
Journal:  Med Oncol       Date:  2014-11-01       Impact factor: 3.064

2.  MET is a predictive factor for late recurrence but not for overall survival of early stage hepatocellular carcinoma.

Authors:  Young Wha Koh; Yang-Soon Park; Hyo Jeong Kang; Ju Hyun Shim; Eunsil Yu
Journal:  Tumour Biol       Date:  2015-02-10

3.  Isolation of Fully Human Antagonistic RON Antibodies Showing Efficient Block of Downstream Signaling and Cell Migration.

Authors:  Zeynep Gunes; Adriana Zucconi; Mario Cioce; Annalisa Meola; Monica Pezzanera; Stefano Acali; Immacolata Zampaglione; Valeria De Pratti; Luca Bova; Fabio Talamo; Anna Demartis; Paolo Monaci; Nicola La Monica; Gennaro Ciliberto; Alessandra Vitelli
Journal:  Transl Oncol       Date:  2011-02-01       Impact factor: 4.243

Review 4.  Strategies of targeting the extracellular domain of RON tyrosine kinase receptor for cancer therapy and drug delivery.

Authors:  Omid Zarei; Silvia Benvenuti; Fulya Ustun-Alkan; Maryam Hamzeh-Mivehroud; Siavoush Dastmalchi
Journal:  J Cancer Res Clin Oncol       Date:  2016-08-08       Impact factor: 4.553

5.  Inhibitors of HGFA, Matriptase, and Hepsin Serine Proteases: A Nonkinase Strategy to Block Cell Signaling in Cancer.

Authors:  Zhenfu Han; Peter K W Harris; Darin E Jones; Ryan Chugani; Tommy Kim; Manjula Agarwal; Wei Shen; Scott A Wildman; James W Janetka
Journal:  ACS Med Chem Lett       Date:  2014-10-09       Impact factor: 4.345

Review 6.  Targeting the HGF/c-MET pathway in hepatocellular carcinoma.

Authors:  Lipika Goyal; Mandar D Muzumdar; Andrew X Zhu
Journal:  Clin Cancer Res       Date:  2013-02-06       Impact factor: 12.531

Review 7.  Targeted and Immune-Based Therapies for Hepatocellular Carcinoma.

Authors:  Tim F Greten; Chunwei Walter Lai; Guangfu Li; Kevin F Staveley-O'Carroll
Journal:  Gastroenterology       Date:  2018-10-01       Impact factor: 22.682

8.  Decorin deficiency promotes hepatic carcinogenesis.

Authors:  Zsolt Horváth; Ilona Kovalszky; Alexandra Fullár; Katalin Kiss; Zsuzsa Schaff; Renato V Iozzo; Kornélia Baghy
Journal:  Matrix Biol       Date:  2013-12-18       Impact factor: 11.583

Review 9.  Met-related receptor tyrosine kinase Ron in tumor growth and metastasis.

Authors:  Purnima K Wagh; Belinda E Peace; Susan E Waltz
Journal:  Adv Cancer Res       Date:  2008       Impact factor: 6.242

10.  The Met protooncogene is a transcriptional target of NF kappaB: implications for cell survival.

Authors:  James Y Dai; Marie C DeFrances; Chunbin Zou; Carla J Johnson; Reza Zarnegar
Journal:  J Cell Biochem       Date:  2009-08-15       Impact factor: 4.429

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.